



Audit Committee – 2025 Operational Summary

Date	Discussion Item	Resolutions
2025/03/05	<ul style="list-style-type: none">• The Company's 2024 Statement on Internal Control• Evaluation on the Company CPA's independence and competency• 2024 Business Operation Report and Financial Statements• 2024 Surplus Distribution in the form of Cash Dividend• Proposal to issue restricted shares awards plan• Proposal to formulate the general principles for the company's pre-approved non-assurance service policy• To revise the Internal Control Self-Assessment Procedure• Proposal to discharge the Company's manager's non compete clause• Proposal to formulate the record date of cash capital increase for the Company's 2020 and 2022 employee stock option exercised and the Company's 3rd domestic unsecured• Proposal to issue the Company's 2024 first employee stock options to non-manager• Transfer the treasury stock to non-manager in accordance to "2022 Stock Repurchase and Transfer to Employee Program"	Unanimously approved by all attending Audit Committee members without objection
2025/04/08	<ul style="list-style-type: none">• To revise the Company's "2022 Stock Repurchase and Transfer to Employee Program"• To buyback the Company's shares	Unanimously approved by all attending Audit Committee members without objection
2025/05/14	<ul style="list-style-type: none">• Proposal for the company's consolidated financial report for the first quarter of 2025• Proposal to formulate the record date of cash capital increase for the Company's 2020 and 2022 employee stock option exercised and the Company's 3rd domestic unsecured• Proposal to authorize the chairman to handle the operating asset transfer and partial asset disposal of the 100% material subsidiary Upsher-Smith• Proposal to provide a loan guarantee amounted to USD 20 million to subsidiary Bora Pharmaceuticals Inc.	Unanimously approved by all attending Audit Committee members without objection

	<ul style="list-style-type: none"> • Proposal to provide a loan guarantee amounted to USD 70 million to subsidiary Upsher-Smith Laboratories, LLC • Proposal for the Company's 100% owned subsidiary Bora Pharmaceuticals Injectables Inc. to purchase the operating asset • Transfer the treasury stock to non-manager in accordance to "2022 Stock Repurchase and Transfer to Employee Program" 	
2025/05/23	<ul style="list-style-type: none"> • Proposal to participate the cash capital increase of the Company's investment company Tanvex BioPharma, Inc. • Proposal to provide a loan guarantee amounted to USD 15 million to subsidiary Bora Pharmaceuticals Injectables Inc. • To revise the terms and conditions for the Company's 3rd domestic unsecured convertible corporate bonds • To revise the terms and conditions for the Company's 1st oversea unsecured zero coupon euro convertible bonds 	Unanimously approved by all attending Audit Committee members without objection
2025/06/13	<ul style="list-style-type: none"> • Proposal for the Company to participate the cash capital increase to Bora Pharmaceutical and Consumer Health Inc. • Proposal for the Company's subsidiary Twi Pharmaceuticals, Inc. to sell two R&D project • Transfer the treasury stock to non-manager in accordance to "2022 Stock Repurchase and Transfer to Employee Program" 	Unanimously approved by all attending Audit Committee members without objection
2025/08/08	<ul style="list-style-type: none"> • Proposal for the company's consolidated financial report for the second quarter of 2025 • Proposal to distribute the Company's earnings for the first half of 2025 • Proposal to formulate the record date of cash capital increase for the Company's 2020 and 2022 employee stock option exercised and the Company's 3rd domestic unsecured convertible corporate bonds • Proposal for the Company to participate the cash capital increase of USD \$40,000 to Bora Global Ltd., a newly established 100% owned subsidiary in the British Virgin Islands • Proposal to revise the Company's 2025 restricted shares awards plan • Proposal to issue the employee stock option • Transfer the treasury stock to non-manager in accordance to "2022 Stock Repurchase and Transfer to Employee Program" 	Unanimously approved by all attending Audit Committee members without objection



	<ul style="list-style-type: none">· Proposal to issue the Company's 2024 first employee stock options to manager· Proposal to issue the Company's 2025 restricted shares awards plan to manager	
2025/10/13	<ul style="list-style-type: none">· Proposal for the Company to participate the overseas depository receipts in the U.S. over-the-counter market with its already issued shares	Unanimously approved by all attending Audit Committee members without objection
2025/11/13	<ul style="list-style-type: none">· Proposal for the company's consolidated financial report for the third quarter of 2025· Proposal to issue the Company's 4th and 5th domestic unsecured convertible corporate bonds· Proposal to discharge the Company's manager's non compete clause· To buyback the Company's shares	Unanimously approved by all attending Audit Committee members without objection
2025/12/04	<ul style="list-style-type: none">· Proposal to set the capital increase base date for the issuance of new shares related to the 2025 exercise of employee stock options granted in 2020, 2022 and 2023 and the conversion of the third domestic unsecured convertible bonds into new shares	Unanimously approved by all attending Audit Committee members without objection
2025/12/16	<ul style="list-style-type: none">· The Company's 2026 internal audit plan· Amendment on the internal control system· To revise the Company's 2025 first employee stock options· Transfer the treasury stock to non-manager in accordance to "2022 Stock Repurchase and Transfer to Employee Program"	Unanimously approved by all attending Audit Committee members without objection